Posters

    Cigarette‐smoke‐dependent changes in the respiratory and cardiovascular system of spontaneously hypertensive (SH) rats and the effect of smoking cessation

    Berges, A.; Friedrichs, B.; Gallitz, I.; Quadt-Humme, S.; Steffen, Y.; Stolle, K.; Lebrun, S.; Lietz, M.

    Conference date
    Mar 6, 2011
    Conference name
    Society of Toxicology (SOT) 2011
    Link to more information
    Topic
    Summary

    Previously, we have shown that cigarette smoke affects cardiac function, hypertrophy status, and serum proteins in SH rats (abstract 912; 48th Annual Meeting & ToxExpoTM [2009]). Here, we investigate the reversibility of these effects after smoking cessation (SC). SH rats were exposed to diluted cigarette mainstream smoke (MS) from the reference cigarette 3R4F (MS-only; 900 µg total particulate matter/day; 5 days/week) or to fresh air (SHAM) for 90 days. SC experiments covered exposure for 30 days MS + 60 days SHAM (SC-1) and 60 days MS + 30 days SHAM (SC-2). Endpoints tested were body weight, heart hypertrophy status, neutrophils in bronchioalveolar lavage fluid, expression levels of matrix metalloproteinase-1 (MMP-1) and metallopeptidase inhibitor-1 (TIMP-1). At 90 days, parameters were decreased (body weight) or increased (all other endpoints) in the MS-only group compared to both cessations groups, which, importantly, display a SHAM-like phenotype: body weight [g]: 275.9+16.8 (MS-only), 316.0±18.5 (SC-1), 311.8+19.6 (SC-2), 301.7±28.7 (SHAM); hypertrophy status [left ventricle weight (g)/tibia length (mm)]: 0.023±0.002 (MS-only), 0.020±0.001 (SC-1), 0.021±0.001 (SC-2), 0.019±0.002 (SHAM); TIMP-1 [pg/ml]: 1990.0±219.6 (MS-only), 247.0±12.4 (SC-1), 234.7±11.5 (SC-2), 270.6±19.7 (SHAM); MMP-1 [ng/ml]: 7.3±0.4 (MS-only), 3.2±0.4 (SC-1), 3.0±0.4 (SC-2), 3.8±0.6 (SHAM); neutrophil count [%]: 12.7±1.1 (MS-only), 0.7±0.1 (SC-1), 3.6±0.6 (SC-2), 0.4±0.1 (SHAM). Further endpoints are currently under investigation. Hence, this experimental format may turn out to be suitable to evaluate respiratory and cardiovascular effects of potentially reduced-risk tobacco products. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.